We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Could Predict Likelihood of Breast Cancer Spreading to The Bone

By LabMedica International staff writers
Posted on 03 Jul 2025

When breast cancer spreads to other parts of the body, it becomes secondary or metastatic breast cancer—a stage that, while treatable, is currently incurable. More...

The bone is the most common site for this spread, and secondary tumors in the bone can cause severe symptoms and a significant decline in quality of life. This can occur months or even years after initial treatment, and currently, there is no reliable way to predict who is most at risk. Researchers are now working on a blood-based method to detect early warning signs, with the goal of identifying patients at higher risk before metastasis occurs.

Researchers at The University of Sheffield (Sheffield, UK who are developing this solution had previously identified 16 proteins produced by breast cancer cells that are primed to spread to bone. These proteins can be detected in blood during the early stages of the disease, before metastasis has occurred. In the current study, the team will analyze blood samples from up to 400 people with primary breast cancer who took part in two large clinical trials. These participants were followed for five to ten years to determine whether they later developed secondary breast cancer. Using advanced computational techniques, the researchers aim to determine which combination of proteins is most predictive of bone metastasis. The end goal is to create a test based on three to five key proteins to assess each patient’s individual risk.

The team will evaluate how well this panel of proteins performs in identifying patients at risk of bone metastasis. If successful, the test could lead to a new approach in breast cancer care, helping doctors tailor treatment and monitoring strategies based on individual risk. The researchers hope this blood test will support those at high risk with more proactive care, while also sparing those at lower risk from unnecessary treatments. The test could ultimately change how breast cancer patients are followed up after treatment and contribute to earlier, more targeted interventions.

“Secondary breast cancer is currently incurable. And when secondary tumors form in the bone, they can cause debilitating symptoms and reduce people’s quality of life,” said Professor Janet Brown, Professor of Translational Medical Oncology. “This can occur months or even years after treatment, and there’s currently no way to know who this will affect. My team’s working on creating a blood test to predict the risk of future breast cancer spreading to the bone, so that we can better support people at higher risk, while sparing those at lower risk from unnecessary treatments.”

Related Links:
The University of Sheffield


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more

Pathology

view channel
Image: A tool uses artificial intelligence and high-resolution imaging to track senescent cells (Courtesy of Adobe Stock)

AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease

Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.